Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through video calls and online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
For medical questions, we encourage you to review our information with your doctor.
Chimeric antigen receptor (CAR) T-cell therapy is a type of cancer immunotherapy. It helps the body’s own immune system find and attack cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside certain immune cells to help them attack the cancer.
To make this treatment, immune cells called T cells are taken from the person’s blood during a process called leukapheresis. Blood is removed through an IV line and goes into a machine that takes out the T cells. The remaining blood then goes back into the body. This process typically takes a few hours, and it might need to be repeated.
The T cells are then frozen and sent to a lab, where they are genetically altered so they have specific receptors (called chimeric antigen receptors, or CARs) on their surface. These receptors help the T cells attach to proteins on cancer cells. The T cells are then multiplied in the lab, which typically takes several weeks.
Once the CAR T cells are ready, the patient gets chemotherapy for a few days to help prepare the body. Then the CAR T cells are infused back into the patient’s blood, where they can seek out the cancer cells and help the immune system attack them.
Idecabtagene vicleucel (ide-cel, Abecma) and ciltacabtagene autoleucel (cilta-cel, Carvykti) are CAR T-cell therapies that target the BCMA protein, which is found on myeloma cells. Either of these treatments can be used in patients who have already received several (typically at least 4) other types of treatment for their multiple myeloma.
These treatments can have serious or even life-threatening side effects, so they need to be given in a medical center that is specially trained in their use. Your health care team will watch you closely for several weeks after you get the CAR T cells.
Cytokine release syndrome (CRS): CRS can happen when T cells release chemicals (cytokines) that ramp up the immune system. CRS most often happens within a few days to weeks after treatment, and in some cases it can be life-threatening. Symptoms can include:
Nervous system problems: This treatment can sometimes have serious effects on the nervous system, which can result in symptoms such as:
Because of the risk of these side effects, you’ll be advised not to drive, operate heavy machinery, or do any other potentially dangerous activities for at least 8 weeks after you get your treatment.
Other serious side effects: Other possible serious side effects can include:
It’s very important to report any side effects to your health care team right away, as there are often medicines that can help treat them.
To learn more about this type of treatment, see CAR T-cell Therapy and Its Side Effects.
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.
Celgene Corporation. ABECMA US Prescribing Information. 2021. Accessed at https://www.fda.gov/media/147055/download on March 31, 2021.
Janssen Pharmaceutical Companies. CARVYKTI US Prescribing Information. 2022. Accessed at https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/CARVYKTI-pi.pdf on March 1, 2022.
Last Revised: March 1, 2022